Cost‐Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers
Advanced Science · 2025
DOI: 10.1002/advs.202411945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Tian Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis, DNA Methylation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Dawn Project Foundation of Shanghai, Shanghai Health and Hygiene Discipline Leader Project.
Abstract (Originalsprache)
Early detection of hepatocellular carcinoma (HCC) in patients with liver cirrhosis (LC) and/or hepatitis virus B/C infection (HVI) improves survival, highlighting the need for accurate, affordable diagnostic tools. Here, 11 methylated DNA markers (MDMs) are identified during marker discovery. In phase I, each selected MDM is validated in 175 plasma samples (HCC, n = 85; LC/HVI, n = 72) by the CO‐methylation aMplification rEal‐Time PCR (COMET) assay. Of these, 8 MDMs are qualified for phase II study, where a logistic regression model (COMET‐LR) is trained and validated with 336 plasma samples (HCC, n = 211; LC/HVI, n = 113; training vs validation, 2:1). In the validation, the COMET‐LR achieved 90.0% sensitivity at 97.4% specificity. Notably, sensitivity in patients with TNM stage I, diameter
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, China.
- Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, Jilin, 130021, China.
- Phase I clinical trials unit, First Hospital of Jilin University, Changchun, Jilin, 130021, China.
- Department of Hepatobiliary Surgery II, General Surgery Center, Zhujiang Hospital, Southern Medical University, Guangzhou, 510280, China.
- Burning Rock Biotech, Guangzhou, 510300, China.
ORCID-Profile: Tian Yang
Förderung
- National Natural Science Foundation of China
- Dawn Project Foundation of Shanghai
- Shanghai Health and Hygiene Discipline Leader Project
- Shanghai Outstanding Academic Leader Program
- Natural Science Foundation of Shanghai
- Shanghai Science and Technology Committee Rising-Star Program
- Key Research and Development Plan of Guangzhou
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Yang, T., Wang, M., Wang, N., Pan, M., Xu, Y., You, Q., Yao, L., Xu, J., Gu, L., Sun, X., Zhang, L., Xu, J., Li, B., Wang, G., Cai, S., Lv, G., & Shen, F. (2025). Cost‐Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers. Advanced Science. https://doi.org/10.1002/advs.202411945
Vancouver
Yang T, Wang M, Wang N, Pan M, Xu Y, You Q, et al. Cost‐Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers. Advanced Science. 2025. doi:10.1002/advs.202411945
BibTeX
@article{Yang2025,
author = {Yang, Tian and Wang, Mingda and Wang, Nanya and Pan, Mingxin and Xu, Yu and You, Qiancheng and Yao, Lanqing and Xu, Jiahao and Gu, Lihui and Sun, Xiaodong and Zhang, Lei and Xu, Jiayue and Li, Bingsi and Wang, Guoqiang and Cai, Shangli and Lv, Guoyue and Shen, Feng},
title = {Cost‐Effective Identification of Hepatocellular Carcinoma from Cirrhosis or Chronic Hepatitis Virus Infection Using Eight Methylated Plasma DNA Markers},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202411945}
}
EUVIMED